Guizhou Salvage Pharmaceutical Co.,Ltd. Logo

Guizhou Salvage Pharmaceutical Co.,Ltd.

600227.SS

(1.0)
Stock Price

2,47 CNY

0.07% ROA

0.1% ROE

1295.71x PER

Market Cap.

3.472.015.258,00 CNY

41.24% DER

0% Yield

0.12% NPM

Guizhou Salvage Pharmaceutical Co.,Ltd. Stock Analysis

Guizhou Salvage Pharmaceutical Co.,Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Guizhou Salvage Pharmaceutical Co.,Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (37%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (1.9x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Assets Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

4 ROE

The stock's ROE indicates a negative return (-14.65%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-9.1%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-23), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Guizhou Salvage Pharmaceutical Co.,Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Guizhou Salvage Pharmaceutical Co.,Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Guizhou Salvage Pharmaceutical Co.,Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Guizhou Salvage Pharmaceutical Co.,Ltd. Revenue
Year Revenue Growth
1996 562.595.458
1997 582.059.006 3.34%
1998 621.798.850 6.39%
1999 598.795.988 -3.84%
2000 600.867.609 0.34%
2001 630.644.450 4.72%
2002 659.393.192 4.36%
2003 589.468.585 -11.86%
2004 731.494.222 19.42%
2005 874.234.153 16.33%
2006 852.923.602 -2.5%
2007 1.113.692.840 23.41%
2008 1.148.163.743 3%
2009 1.112.171.875 -3.24%
2010 1.329.324.703 16.34%
2011 1.960.950.050 32.21%
2012 3.504.164.632 44.04%
2013 4.149.879.864 15.56%
2014 3.286.700.284 -26.26%
2015 2.761.478.183 -19.02%
2016 2.856.923.346 3.34%
2017 1.692.959.399 -68.75%
2018 2.430.806.758 30.35%
2019 2.026.286.236 -19.96%
2020 1.926.852.891 -5.16%
2021 2.181.369.746 11.67%
2022 2.517.340.257 13.35%
2023 2.333.825.702 -7.86%
2023 2.245.779.037 -3.92%
2024 2.518.844.120 10.84%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Guizhou Salvage Pharmaceutical Co.,Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 2.797.508 100%
2011 4.151.791 32.62%
2012 5.144.772 19.3%
2013 11.442.158 55.04%
2014 4.553.860 -151.26%
2015 85.030 -5255.59%
2016 28.203.690 99.7%
2017 26.141.882 -7.89%
2018 56.401.973 53.65%
2019 73.476.284 23.24%
2020 72.434.975 -1.44%
2021 95.625.800 24.25%
2022 96.691.308 1.1%
2023 126.249.594 23.41%
2023 102.590.317 -23.06%
2024 62.979.500 -62.89%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Guizhou Salvage Pharmaceutical Co.,Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 27.351.702
1997 27.113.540 -0.88%
1998 24.584.552 -10.29%
1999 23.742.058 -3.55%
2000 26.556.430 10.6%
2001 25.938.922 -2.38%
2002 42.247.015 38.6%
2003 45.887.953 7.93%
2004 57.193.967 19.77%
2005 77.426.643 26.13%
2006 128.374.761 39.69%
2007 139.225.207 7.79%
2008 153.275.759 9.17%
2009 160.232.151 4.34%
2010 55.385.411 -189.3%
2011 50.019.685 -10.73%
2012 98.036.618 48.98%
2013 55.614.569 -76.28%
2014 45.531.637 -22.14%
2015 37.821.349 -20.39%
2016 58.571.866 35.43%
2017 74.874.469 21.77%
2018 24.713.152 -202.97%
2019 27.483.223 10.08%
2020 45.379.564 39.44%
2021 30.956.249 -46.59%
2022 45.232.950 31.56%
2023 374.672.504 87.93%
2023 109.694.579 -241.56%
2024 -88.011.213 224.64%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Guizhou Salvage Pharmaceutical Co.,Ltd. EBITDA
Year EBITDA Growth
1996 74.441.109
1997 84.346.012 11.74%
1998 85.419.874 1.26%
1999 96.646.257 11.62%
2000 78.293.262 -23.44%
2001 67.053.490 -16.76%
2002 95.506.043 29.79%
2003 87.705.862 -8.89%
2004 152.380.773 42.44%
2005 250.820.045 39.25%
2006 280.148.346 10.47%
2007 303.252.494 7.62%
2008 298.462.531 -1.6%
2009 343.200.395 13.04%
2010 241.409.651 -42.17%
2011 222.450.696 -8.52%
2012 420.787.047 47.13%
2013 580.349.943 27.49%
2014 -40.120.797 1546.51%
2015 564.060.664 107.11%
2016 331.335.718 -70.24%
2017 439.447.281 24.6%
2018 650.696.694 32.47%
2019 323.098.801 -101.39%
2020 371.993.648 13.14%
2021 236.202.926 -57.49%
2022 5.013.198 -4611.62%
2023 -243.735.621 102.06%
2023 231.537.547 205.27%
2024 114.991.412 -101.35%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Guizhou Salvage Pharmaceutical Co.,Ltd. Gross Profit
Year Gross Profit Growth
1996 120.304.602
1997 125.437.525 4.09%
1998 109.483.296 -14.57%
1999 99.877.902 -9.62%
2000 72.400.955 -37.95%
2001 40.406.336 -79.18%
2002 108.677.019 62.82%
2003 117.408.432 7.44%
2004 210.610.994 44.25%
2005 308.141.403 31.65%
2006 295.068.624 -4.43%
2007 426.166.795 30.76%
2008 458.103.275 6.97%
2009 464.960.860 1.47%
2010 362.008.442 -28.44%
2011 423.085.958 14.44%
2012 390.287.844 -8.4%
2013 521.403.603 25.15%
2014 -38.284.560 1461.92%
2015 244.780.539 115.64%
2016 534.951.782 54.24%
2017 478.504.453 -11.8%
2018 846.047.878 43.44%
2019 487.276.225 -73.63%
2020 604.439.102 19.38%
2021 421.676.784 -43.34%
2022 145.569.238 -189.67%
2023 116.098.275 -25.38%
2023 177.296.735 34.52%
2024 284.953.900 37.78%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Guizhou Salvage Pharmaceutical Co.,Ltd. Net Profit
Year Net Profit Growth
1996 47.189.598
1997 51.978.028 9.21%
1998 46.843.755 -10.96%
1999 55.685.048 15.88%
2000 65.133.301 14.51%
2001 37.515.717 -73.62%
2002 61.259.168 38.76%
2003 71.352.219 14.15%
2004 105.614.607 32.44%
2005 175.085.268 39.68%
2006 170.627.164 -2.61%
2007 192.206.576 11.23%
2008 165.878.425 -15.87%
2009 137.417.593 -20.71%
2010 125.298.468 -9.67%
2011 92.854.284 -34.94%
2012 35.290.238 -163.12%
2013 11.074.977 -218.65%
2014 -574.699.894 101.93%
2015 20.248.315 2938.26%
2016 -349.534.191 105.79%
2017 36.711.602 1052.11%
2018 197.329.127 81.4%
2019 -1.711.930.967 111.53%
2020 55.605.342 3178.72%
2021 -56.643.806 198.17%
2022 -371.483.500 84.75%
2023 -348.991.156 -6.44%
2023 -119.274.850 -192.59%
2024 13.750.764 967.41%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Guizhou Salvage Pharmaceutical Co.,Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 1 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 -1 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 -1 100%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Guizhou Salvage Pharmaceutical Co.,Ltd. Free Cashflow
Year Free Cashflow Growth
1998 52.934.587
1999 -31.526.129 267.91%
2000 -24.978.988 -26.21%
2001 81.848.493 130.52%
2002 39.783.579 -105.73%
2003 90.676.187 56.13%
2004 145.271.933 37.58%
2005 52.760.548 -175.34%
2006 94.221.706 44%
2007 -660.430.730 114.27%
2008 -1.522.080.147 56.61%
2009 -1.697.561.951 10.34%
2010 -1.232.732.060 -37.71%
2011 -706.639.673 -74.45%
2012 147.754.299 578.25%
2013 -63.698.631 331.96%
2014 194.938.545 132.68%
2015 -15.893.384 1326.54%
2016 -167.609.025 90.52%
2017 -336.676.078 50.22%
2018 364.636.693 192.33%
2019 34.720.907 -950.19%
2020 155.043.503 77.61%
2021 74.310.167 -108.64%
2022 -255.446.655 129.09%
2023 104.879.082 343.56%
2023 -64.942.414 261.5%
2024 77.910.288 183.36%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Guizhou Salvage Pharmaceutical Co.,Ltd. Operating Cashflow
Year Operating Cashflow Growth
1998 56.625.477
1999 62.979.308 10.09%
2000 701.704 -8875.2%
2001 153.762.191 99.54%
2002 67.427.317 -128.04%
2003 95.579.229 29.45%
2004 155.195.242 38.41%
2005 339.377.301 54.27%
2006 224.660.970 -51.06%
2007 258.217.509 13%
2008 277.290.756 6.88%
2009 303.459.046 8.62%
2010 95.499.725 -217.76%
2011 383.970.770 75.13%
2012 592.122.978 35.15%
2013 183.510.247 -222.66%
2014 339.410.397 45.93%
2015 38.264.931 -787%
2016 129.178.627 70.38%
2017 -32.546.822 496.9%
2018 523.349.443 106.22%
2019 140.093.494 -273.57%
2020 264.557.038 47.05%
2021 276.666.953 4.38%
2022 195.615.283 -41.43%
2023 307.992.942 36.49%
2023 0 0%
2024 116.889.475 100%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Guizhou Salvage Pharmaceutical Co.,Ltd. Capital Expenditure
Year Capital Expenditure Growth
1998 3.690.890
1999 94.505.437 96.09%
2000 25.680.692 -268%
2001 71.913.697 64.29%
2002 27.643.737 -160.14%
2003 4.903.041 -463.81%
2004 9.923.309 50.59%
2005 286.616.752 96.54%
2006 130.439.263 -119.73%
2007 918.648.239 85.8%
2008 1.799.370.903 48.95%
2009 2.001.020.997 10.08%
2010 1.328.231.785 -50.65%
2011 1.090.610.443 -21.79%
2012 444.368.679 -145.43%
2013 247.208.878 -79.75%
2014 144.471.851 -71.11%
2015 54.158.315 -166.76%
2016 296.787.652 81.75%
2017 304.129.256 2.41%
2018 158.712.750 -91.62%
2019 105.372.586 -50.62%
2020 109.513.534 3.78%
2021 202.356.785 45.88%
2022 451.061.938 55.14%
2023 203.113.860 -122.07%
2023 64.942.414 -212.76%
2024 38.979.187 -66.61%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Guizhou Salvage Pharmaceutical Co.,Ltd. Equity
Year Equity Growth
1996 89.304.561
1997 97.101.266 8.03%
1998 151.322.522 35.83%
1999 677.974.345 77.68%
2000 700.607.647 3.23%
2001 721.123.365 2.84%
2002 748.382.533 3.64%
2003 819.734.752 8.7%
2004 891.349.359 8.03%
2005 1.228.434.628 27.44%
2006 1.365.061.793 10.01%
2007 1.871.594.987 27.06%
2008 2.018.113.868 7.26%
2009 2.581.034.972 21.81%
2010 3.911.240.250 34.01%
2011 4.002.651.319 2.28%
2012 3.562.104.358 -12.37%
2013 3.551.928.235 -0.29%
2014 3.022.906.476 -17.5%
2015 3.054.856.233 1.05%
2016 4.610.557.396 33.74%
2017 4.637.797.938 0.59%
2018 4.860.326.216 4.58%
2019 3.177.501.222 -52.96%
2020 3.229.903.080 1.62%
2021 3.170.050.010 -1.89%
2022 2.798.761.416 -13.27%
2023 2.671.655.642 -4.76%
2023 2.529.738.545 -5.61%
2024 2.619.936.131 3.44%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Guizhou Salvage Pharmaceutical Co.,Ltd. Assets
Year Assets Growth
1996 205.342.056
1997 261.635.140 21.52%
1998 314.711.911 16.87%
1999 789.463.119 60.14%
2000 843.264.825 6.38%
2001 901.548.781 6.46%
2002 868.515.680 -3.8%
2003 970.407.710 10.5%
2004 1.035.795.022 6.31%
2005 1.540.323.690 32.75%
2006 1.733.981.027 11.17%
2007 2.697.522.200 35.72%
2008 4.688.136.856 42.46%
2009 8.668.089.080 45.91%
2010 9.570.178.668 9.43%
2011 10.106.658.972 5.31%
2012 8.197.143.792 -23.29%
2013 8.075.464.944 -1.51%
2014 7.229.924.246 -11.7%
2015 7.260.115.326 0.42%
2016 7.163.183.925 -1.35%
2017 6.914.423.605 -3.6%
2018 6.668.953.203 -3.68%
2019 4.705.287.386 -41.73%
2020 4.655.407.666 -1.07%
2021 4.602.167.789 -1.16%
2022 4.616.625.445 0.31%
2023 4.736.516.834 2.53%
2023 4.719.299.653 -0.36%
2024 4.865.946.585 3.01%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Guizhou Salvage Pharmaceutical Co.,Ltd. Liabilities
Year Liabilities Growth
1996 116.037.494
1997 164.533.874 29.48%
1998 163.389.388 -0.7%
1999 111.488.774 -46.55%
2000 142.657.177 21.85%
2001 180.425.415 20.93%
2002 120.133.147 -50.19%
2003 150.672.957 20.27%
2004 144.445.662 -4.31%
2005 311.889.062 53.69%
2006 368.919.234 15.46%
2007 825.927.212 55.33%
2008 2.670.022.986 69.07%
2009 6.087.054.106 56.14%
2010 5.658.938.417 -7.57%
2011 6.104.007.652 7.29%
2012 4.635.039.434 -31.69%
2013 4.523.536.708 -2.46%
2014 4.207.017.769 -7.52%
2015 4.205.259.092 -0.04%
2016 2.551.568.732 -64.81%
2017 2.276.625.667 -12.08%
2018 1.808.626.986 -25.88%
2019 1.527.786.163 -18.38%
2020 1.425.504.585 -7.18%
2021 1.432.117.778 0.46%
2022 1.817.864.028 21.22%
2023 2.064.861.192 11.96%
2023 2.189.561.108 5.7%
2024 2.246.010.454 2.51%

Guizhou Salvage Pharmaceutical Co.,Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.32
Net Income per Share
0
Price to Earning Ratio
1295.71x
Price To Sales Ratio
1.56x
POCF Ratio
9.17
PFCF Ratio
22.4
Price to Book Ratio
1.33
EV to Sales
1.92
EV Over EBITDA
34.58
EV to Operating CashFlow
11.26
EV to FreeCashFlow
27.51
Earnings Yield
0
FreeCashFlow Yield
0.04
Market Cap
3,47 Bil.
Enterprise Value
4,26 Bil.
Graham Number
0.24
Graham NetNet
-1.02

Income Statement Metrics

Net Income per Share
0
Income Quality
141.34
ROE
0
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
-0.37
EBT Per Ebit
-4.34
Ebit per Revenue
0
Effective Tax Rate
1.15

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0.04
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.09
Operating Profit Margin
0
Pretax Profit Margin
-0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
20.18
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.22
Free CashFlow per Share
0.09
Capex to Operating CashFlow
0.59
Capex to Revenue
0.1
Capex to Depreciation
1.01
Return on Invested Capital
-0
Return on Tangible Assets
0
Days Sales Outstanding
58.58
Days Payables Outstanding
110.71
Days of Inventory on Hand
49.83
Receivables Turnover
6.23
Payables Turnover
3.3
Inventory Turnover
7.33
Capex per Share
0.13

Balance Sheet

Cash per Share
0,07
Book Value per Share
1,55
Tangible Book Value per Share
0.98
Shareholders Equity per Share
1.55
Interest Debt per Share
0.67
Debt to Equity
0.41
Debt to Assets
0.22
Net Debt to EBITDA
6.42
Current Ratio
0.57
Tangible Asset Value
1,65 Bil.
Net Current Asset Value
-1,26 Bil.
Invested Capital
2954686865
Working Capital
-0,74 Bil.
Intangibles to Total Assets
0.2
Average Receivables
0,34 Bil.
Average Payables
0,57 Bil.
Average Inventory
262112747.5
Debt to Market Cap
0.31

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Guizhou Salvage Pharmaceutical Co.,Ltd. Dividends
Year Dividends Growth
2001 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2012 0 0%
2013 0 0%
2014 0 0%

Guizhou Salvage Pharmaceutical Co.,Ltd. Profile

About Guizhou Salvage Pharmaceutical Co.,Ltd.

Guizhou Salvage Pharmaceutical Co.,Ltd. produces and sells urea and methanol in China. The company offers urea fertilizers under the Chi brand; methanol products; and ammonium sulfate, chlorine, and potassium sulfate fertilizers. It also produces and sells medicines, medical devices, and health products for diabetes, cardiovascular, skin disease, gynecology, respiratory tract, digestive system, endocrine, mental nerve, heart, kidney, blood system, circulatory system, and nervous system areas. The company was formerly known as Guizhou Chitianhua Co., Ltd. Guizhou Salvage Pharmaceutical Co.,Ltd. was founded in 1998 and is based in Guiyang, China.

CEO
Mr. Lin Hong Ding
Employee
1.890
Address
Qingzhen Medical Park
Guiyang, 551400

Guizhou Salvage Pharmaceutical Co.,Ltd. Executives & BODs

Guizhou Salvage Pharmaceutical Co.,Ltd. Executives & BODs
# Name Age
1 Ms. Hongyan Wu
Deputy GM
70
2 Mr. Bi Lu Che
Deputy General Manager
70
3 Mr. Yong Ye
Chief Financial Officer
70
4 Mr. Honglin Chen
Deputy GM
70
5 Ms. Min Hong Gao
Executive Deputy GM & Director
70
6 Ms. Zheng Hong Xian
Deputy GM & Board Secretary
70
7 Mr. Lin Hong Ding
Chairman & GM
70

Guizhou Salvage Pharmaceutical Co.,Ltd. Competitors